Enliven Therapeutics, Inc.
Total Trades
203
Buys
1
Sells
139
Largest Trade
$1M+
Insiders
9
Institutional Funds
94
Inst. Value
$1M+
Activist Filings
38
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Kintz Samuel | PRESIDENT AND CEO | SELL | $50K–$100K | 5K | $16.42 | Apr 21, 2025 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $100K–$500K | 7K | $18.04 | Apr 9, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 3K | $21.33 | Mar 31, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 3K | $2.48 | Mar 31, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 1K | $2.48 | Mar 26, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $15K–$50K | 1K | $22.50 | Mar 26, 2025 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 13K | $20.61 | Mar 21, 2025 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 13K | $20.83 | Mar 19, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 3K | $21.59 | Jan 30, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 3K | $2.48 | Jan 30, 2025 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $500K+ | 28K | $24.18 | Jan 10, 2025 |
| Patel Anish | CHIEF OPERATING OF… | EXERCISE | $15K–$50K | 22K | $1.81 | Jan 10, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $15K–$50K | 14K | $2.48 | Jan 7, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $15K–$50K | 1K | $25.04 | Jan 7, 2025 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 4K | $22.23 | Dec 31, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 4K | $2.48 | Dec 31, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $100K–$500K | 5K | $24.89 | Dec 2, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 5K | $2.48 | Dec 2, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $100K–$500K | 6K | $28.56 | Oct 30, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $15K–$50K | 6K | $2.48 | Oct 30, 2024 |
| Patel Anish | CHIEF OPERATING OF… | SELL | $15K–$50K | 716 | $30.00 | Oct 22, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $15K–$50K | 847 | $30.00 | Oct 22, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $15K–$50K | 924 | $30.00 | Oct 22, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 814 | $2.48 | Oct 22, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $15K–$50K | 814 | $30.00 | Oct 22, 2024 |
| Heyman Richard A. | Director | SELL | $15K–$50K | 2K | $30.00 | Oct 22, 2024 |
| Collins Helen Louise | CHIEF MEDICAL OFFI… | SELL | $15K–$50K | 816 | $30.00 | Oct 22, 2024 |
| Collins Helen Louise | CHIEF MEDICAL OFFI… | EXERCISE | $1K–$15K | 816 | $2.48 | Oct 22, 2024 |
| Heyman Richard A. | Director | SELL | $15K–$50K | 1K | $27.67 | Oct 17, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $1M+ | 51K | $28.11 | Oct 11, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $500K+ | 30K | $28.07 | Oct 11, 2024 |
| Ballal Rahul D. | Director | EXERCISE | $100K–$500K | 10K | $14.10 | Oct 11, 2024 |
| Ballal Rahul D. | Director | SELL | $100K–$500K | 10K | $28.17 | Oct 11, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 10K | $27.54 | Oct 8, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 15K | $27.51 | Oct 8, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $100K–$500K | 11K | $27.51 | Oct 8, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $15K–$50K | 11K | $2.48 | Oct 8, 2024 |
| Heyman Richard A. | Director | SELL | $50K–$100K | 3K | $27.51 | Oct 8, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $1K–$15K | 527 | $27.54 | Oct 3, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $1K–$15K | 526 | $27.54 | Oct 3, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 521 | $2.48 | Oct 3, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $1K–$15K | 521 | $27.54 | Oct 3, 2024 |
| Heyman Richard A. | Director | SELL | $1K–$15K | 518 | $27.54 | Oct 3, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $100K–$500K | 6K | $24.61 | Oct 1, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $15K–$50K | 6K | $2.48 | Oct 1, 2024 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC O… | SELL | $100K–$500K | 12K | $22.49 | Sep 3, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | EXERCISE | $1K–$15K | 4K | $2.48 | Aug 29, 2024 |
| Hohl Benjamin | CHIEF FINANCIAL OF… | SELL | $50K–$100K | 4K | $22.54 | Aug 29, 2024 |
| Kintz Samuel | PRESIDENT AND CEO | SELL | $100K–$500K | 12K | $22.89 | Aug 28, 2024 |
| Heyman Richard A. | Director | SELL | $15K–$50K | 1K | $23.25 | Aug 19, 2024 |
Institutional Ownership
13F filings as of Dec 31, 2025 · 94 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| ORBIMED ADVISORS LLC | 8.0M | $1M+ | SH |
| Fairmount Funds Management LLC | 3.7M | $1M+ | SH |
| VR Adviser, LLC | 3.2M | $1M+ | SH |
| Point72 Asset Management, L.P. | 1.5M | $1M+ | SH |
| Novo Holdings A/S | 1.5M | $1M+ | SH |
| Capital Research Global Investors | 1.3M | $1M+ | SH |
| Pictet Asset Management Holding SA | 1.3M | $1M+ | SH |
| STATE STREET CORP | 1.1M | $1M+ | SH |
| Soleus Capital Management, L.P. | 1.0M | $1M+ | SH |
| GEODE CAPITAL MANAGEMENT, LLC | 911K | $1M+ | SH |
| 5AM Venture Management, LLC | 772K | $1M+ | SH |
| Candriam S.C.A. | 453K | $1M+ | SH |
| Spruce Street Capital LP | 446K | $1M+ | SH |
| DIMENSIONAL FUND ADVISORS LP | 357K | $1M+ | SH |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 355K | $1M+ | SH |
| Logos Global Management LP | 340K | $1M+ | SH |
| Patient Square Capital LP | 308K | $1M+ | SH |
| VANGUARD GROUP INC | 304K | $1M+ | SH |
| SPHERA FUNDS MANAGEMENT LTD. | 227K | $1M+ | SH |
| Exome Asset Management LLC | 222K | $1M+ | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
Venrock Healthcare Capital Partners III, L.P.
SC 13G/A · Nov 14, 2025
5.4%
3.2M shares
SC 13G/A · Nov 5, 2025
13.3%
7.9M shares
SC 13G/A · Aug 14, 2025
9.9%
6.0M shares
Fairmount Funds Management LLC
SC 13G/A · Aug 14, 2025
6.3%
3.7M shares
SC 13G · Aug 14, 2025
5.2%
2.5M shares
SC 13G/A · Jul 17, 2025
5.1%
2.9M shares
SC 13D/A · Jun 17, 2025
13.4%
7.9M shares
Fairmount Funds Management LLC
SC 13G/A · Feb 14, 2025
6.6%
3.2M shares
SC 13G/A · Feb 14, 2025
4.9%
2.4M shares
Venrock Healthcare Capital Partners III, L.P.
SC 13G/A · Nov 14, 2024
8.5%
4.0M shares
SC 13G/A · Nov 14, 2024
2.2%
1.1M shares
SC 13G/A · Nov 14, 2024
3.7%
6 shares
Fairmount Funds Management LLC
SC 13G/A · Nov 14, 2024
6.8%
3.2M shares
SC 13G/A · Nov 14, 2024
8.7%
4.1M shares
SC 13G · Nov 13, 2024
5.7%
2.7M shares
SC 13G · Nov 8, 2024
6.2%
2.9M shares
SC 13G · Oct 24, 2024
6.2%
2.9M shares
SC 13D/A · Jul 29, 2024
4.1%
1.9M shares
SC 13D/A · May 20, 2024
16.8%
7.9M shares
SC 13D/A · Apr 15, 2024
5.1%
2.4M shares
SC 13D/A · Apr 4, 2024
19.2%
9.0M shares
SC 13D/A · Feb 16, 2024
7.8%
3.2M shares
Venrock Healthcare Capital Partners III, L.P.
SC 13G/A · Feb 15, 2024
7.2%
3.0M shares
SC 13G/A · Feb 14, 2024
0.1%
6 shares
SC 13G/A · Feb 14, 2024
5.7%
6 shares
SC 13G/A · Feb 14, 2024
7.0%
2.9M shares
Fairmount Funds Management LLC
SC 13G/A · Feb 14, 2024
5.2%
2.1M shares
SC 13G/A · Feb 14, 2024
0.9%
389K shares
SC 13D/A · Feb 2, 2024
9.4%
3.9M shares
SC 13D/A · Aug 28, 2023
10.9%
4.5M shares
SC 13G · May 10, 2023
10.7%
4.4M shares
Fairmount Funds Management LLC
SC 13G · Apr 27, 2023
5.2%
2.1M shares
SC 13G · Apr 24, 2023
5.1%
2.1M shares
Venrock Healthcare Capital Partners III, L.P.
SC 13G · Mar 13, 2023
5.4%
2.2M shares
SC 13G · Mar 6, 2023
5.6%
6 shares
SC 13D · Mar 6, 2023
11.8%
4.8M shares
SC 13G/A · Feb 28, 2023
3.5%
1.4M shares
SC 13D · Feb 28, 2023
21.8%
8.9M shares